Shanghai AQ BioPharma Co., Ltd.

Shanghai AQ BioPharma Co., Ltd. is a biotech startup founded in 2007 by a team of experienced medicinal chemists and managers from USA pharmaceutical and biotech industries. The company is situated in the heart of the Chinese Pharma Valley - Zhangjiang Hi-Tech Park, Pudong, Shanghai.

Shanghai AQ BioPharma specializes in providing fast delivery of high-quality intermediates, unique building blocks, and other starting materials from grams to kilos. Their offerings aim to accelerate the new drug discovery process and new product development, particularly focusing on rare, novel, and drug-like N-based heterocyclic compounds such as piperidines, azaindoles, and pyrrolidines. Their products primarily target GPCR and Kinase drug discovery projects, with a notable emphasis on the development of fluorinated heterocyclic intermediates, making them the leading FluorMedChem company in China.

Additionally, the company's experienced experts provide medicinal chemistry services including hit to lead, lead optimization, custom synthesis and manufacturing, contract R&D, and process development for pharmaceutical and biotech companies.

The most recent investment in Shanghai AQ BioPharma was a Corporate Round investment at 01 March 2019 by Chenghe Venture Capital. With its strategic location and focus on unique, high-quality products, Shanghai AQ BioPharma is well-positioned for continued success and growth in the biotechnology and healthcare industries.